Knapp C C, Sierra-Madero J, Washington J A
Department of Microbiology, Cleveland Clinic Foundation, Ohio 44195.
Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):511-5. doi: 10.1016/0732-8893(89)90085-0.
Piperacillin/tazobactam (YTR 830; CL-298,741) was tested against fresh and stock clinical isolates of Gram-negative bacilli, as well as against Gram-negative bacilli that had stably derepressed Class I beta-lactamases or that were hyperproductive of non-Class I beta-lactamases. Of 63 clinical isolates of the Enterobacteriaceae with ticarcillin (plus clavulanate) minimum inhibitory concentrations (MICs) of greater than or equal to 128 micrograms/ml, 16 had piperacillin/tazobactam MICs of less than or equal to 16/2 micrograms/ml. Of 48 clinical isolates of Pseudomonas spp. with ticarcillin (plus clavulanate) MICs of greater than or equal to 128 micrograms/ml, 35 had piperacillin/tazobactam MICs of less than or equal to 64/8 micrograms/ml. Tazobactam generally reduced piperacillin MICs by two- to greater than or equal to eightfold against stably derepressed mutants for Class I beta-lactamases.
哌拉西林/他唑巴坦（YTR 830；CL-298,741）针对革兰氏阴性杆菌的新鲜临床分离株和储存临床分离株进行了测试，同时也针对那些稳定去阻遏的I类β-内酰胺酶或高产非I类β-内酰胺酶的革兰氏阴性杆菌进行了测试。在63株对替卡西林（加克拉维酸）最低抑菌浓度（MIC）大于或等于128微克/毫升的肠杆菌科临床分离株中，有16株对哌拉西林/他唑巴坦的MIC小于或等于16/2微克/毫升。在48株对替卡西林（加克拉维酸）MIC大于或等于128微克/毫升的假单胞菌属临床分离株中，有35株对哌拉西林/他唑巴坦的MIC小于或等于64/8微克/毫升。对于稳定去阻遏的I类β-内酰胺酶突变体，他唑巴坦通常可使哌拉西林的MIC降低2至大于或等于8倍。
